Abstract
This case report describes 2 patients with pemphigus and off-label teclistamab use.
Moritz Ronicke, Tobias Rothe, Carola Berking, Ricardo Grieshaber-Bouyer, Michael Sticherling
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Temporal outcomes after rituximab therapy for pemphigus vulgaris.
10.1016/j.jid.2021.09.013 · 2022
Persistence of anti-desmoglein 3 IgG(+) B-cell clones in pemphigus patients over years.
10.1038/jid.2014.291 · 2015
BCMA-targeted T-cell-engager therapy for autoimmune disease.
10.1056/nejmc2408786 · 2024
Long-lived autoreactive plasma cells drive persistent autoimmune inflammation.
10.1038/nrrheum.2011.1 · 2011
Pivotal role of lesional and perilesional T/B lymphocytes in pemphigus pathogenesis.
10.1016/j.jid.2017.05.032 · 2017
First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial.
10.1016/s0140-6736(17)30070-3 · 2017
No additional external references are available.
Confidence 0%